Insights

Innovative Technology Adoption RevBio's TETRANITE platform offers a novel, bioengineered bone adhesive with demonstrated superior performance over traditional fixation methods, providing a compelling value proposition for healthcare providers seeking advanced solutions in orthopedics, neurosurgery, and dental procedures.

Growing Clinical Trials With multiple FDA-approved clinical trials underway, including recent patient enrollments and NIH grants, RevBio is progressing toward market readiness, creating opportunities to engage early adopters and institutional partners interested in cutting-edge regenerative therapies.

Market Expansion Potential Targeting a $10 billion addressable market across diverse medical fields, RevBio's innovative adhesive appeals to a broad range of orthopedic and craniofacial applications, opening avenues for strategic sales efforts in hospitals, surgical centers, and implant manufacturers.

Funding and Support Recent NIH grants and partnerships with academic institutions signal strong research backing and validation, making RevBio an attractive prospect for investors and healthcare systems looking to invest in high-growth, innovative medical device companies.

Regulatory Pathway Advantage The anticipated De Novo classification for multiple indications will expedite commercialization, providing a competitive edge and enabling sales teams to target early adoption via approval-ready solutions with clear regulatory pathways.

RevBio, Inc. Tech Stack

RevBio, Inc. uses 8 technology products and services including Shopify, Element UI, Swiper, and more. Explore RevBio, Inc.'s tech stack below.

  • Shopify
    E-commerce
  • Element UI
    Javascript Frameworks
  • Swiper
    Javascript Libraries
  • HubSpot
    Marketing Automation
  • Yoast SEO
    Search Engines
  • GoDaddy
    Web Hosting
  • Kadence WP Blocks
    Web Platform Extensions
  • Nginx
    Web Servers

RevBio, Inc.'s Email Address Formats

RevBio, Inc. uses at least 2 format(s):
RevBio, Inc. Email FormatsExamplePercentage
FLast@launchpadmedical.comJDoe@launchpadmedical.com
76%
LFirst@launchpadmedical.comDJohn@launchpadmedical.com
10%
Last@launchpadmedical.comDoe@launchpadmedical.com
9%
First.Last@launchpadmedical.comJohn.Doe@launchpadmedical.com
5%
FLast@revbio.comJDoe@revbio.com
70%
Last@revbio.comDoe@revbio.com
30%

Frequently Asked Questions

Where is RevBio, Inc.'s headquarters located?

Minus sign iconPlus sign icon
RevBio, Inc.'s main headquarters is located at 600 Suffolk Street Suite 250 Lowell, Massachusetts 01854 United States. The company has employees across 1 continents, including North America.

What is RevBio, Inc.'s phone number?

Minus sign iconPlus sign icon
You can contact RevBio, Inc.'s main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is RevBio, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
RevBio, Inc.'s official website is revbio.com and has social profiles on LinkedInCrunchbase.

What is RevBio, Inc.'s NAICS code?

Minus sign iconPlus sign icon
RevBio, Inc.'s NAICS code is 3391 - Medical Equipment and Supplies Manufacturing.

How many employees does RevBio, Inc. have currently?

Minus sign iconPlus sign icon
As of March 2026, RevBio, Inc. has approximately 34 employees across 1 continents, including North America. Key team members include Ceo And Founder: B. H.Cfo/Coo & Co-Founder: D. G. A.Chief Marketing Officer: M. T.. Explore RevBio, Inc.'s employee directory with LeadIQ.

What industry does RevBio, Inc. belong to?

Minus sign iconPlus sign icon
RevBio, Inc. operates in the Medical Equipment Manufacturing industry.

What technology does RevBio, Inc. use?

Minus sign iconPlus sign icon
RevBio, Inc.'s tech stack includes ShopifyElement UISwiperHubSpotYoast SEOGoDaddyKadence WP BlocksNginx.

What is RevBio, Inc.'s email format?

Minus sign iconPlus sign icon
RevBio, Inc.'s email format typically follows the pattern of FLast@launchpadmedical.com. Find more RevBio, Inc. email formats with LeadIQ.

How much funding has RevBio, Inc. raised to date?

Minus sign iconPlus sign icon
As of March 2026, RevBio, Inc. has raised $2.4M in funding. The last funding round occurred on Sep 16, 2024 for $2.4M.

When was RevBio, Inc. founded?

Minus sign iconPlus sign icon
RevBio, Inc. was founded in 2014.

RevBio, Inc.

Medical Equipment ManufacturingMassachusetts, United States11-50 Employees

The standard of care for healing broken bones hasn't changed in over fifty years. Invasive metal hardware is still routinely used to fixate bones–often with less-than-optimal patient outcomes. RevBio® is a medical device company that has invented TETRANITE®, a regenerative bone adhesive currently in 150 patients across seven FDA approved clinical trials. Our patented “bone glue” is founded upon a comprehensive patent portfolio with global patent protection extending through 2042. Easily injectable into a range of musculoskeletal defects, TETRANITE has demonstrated superior performance over other standard of care options in curing speed and strength, rate of resorption, bone regeneration, and most critically wet-field adhesion. As a novel technology, TETRANITE is anticipated to receive a De Novo classification for several indications which will expedite the path to commercialization by Q3 2027. Bioengineered for a body of applications, the TETRANITE platform will address a total addressable market of over $10 billion in neurosurgical, orthopaedic and dental use cases.Inspired by the marine animal the sandcastle worm, Tetranite is simple chemistry. Bioengineered from the worm’s secreted protein, our synthetic adhesive is the only patented biomaterial which satisfies both the required and desired properties for a bone adhesive: wet field performance, multi-surface bonding, rapid mechanical stability, and controlled biodegradability.

The properties of Tetranite™ include the ability to provide immediate fixation of bone to bone and bone to metal. This adhesive has been shown in multiple animal studies to be a non-toxic and effective way of repairing bone fractures and defects as well as securing implant devices.  Existing data has also shown that Tetranite™ is reabsorbed and replaced with new bone during the natural process of bone remodeling by acting as a scaffold to facilitate bone growth over time.

Section iconCompany Overview

Headquarters
600 Suffolk Street Suite 250 Lowell, Massachusetts 01854 United States
Phone number
Website
revbio.com
NAICS Code
3391 - Medical Equipment and Supplies Manufacturing
Founded
2014
Employees
11-50

Section iconFunding & Financials

  • $2.4M

    RevBio, Inc. has raised a total of $2.4M of funding over 21 rounds. Their latest funding round was raised on Sep 16, 2024 in the amount of $2.4M.

  • $1M$10M

    RevBio, Inc.'s revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $2.4M

    RevBio, Inc. has raised a total of $2.4M of funding over 21 rounds. Their latest funding round was raised on Sep 16, 2024 in the amount of $2.4M.

  • $1M$10M

    RevBio, Inc.'s revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.